Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
Public ClinicalTrials.gov record NCT04594213. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Study identification
- NCT ID
- NCT04594213
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Merz North America, Inc.
- Industry
- Enrollment
- 362 participants
Conditions and interventions
Interventions
- NT 201 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 22, 2020
- Primary completion
- Apr 14, 2021
- Completion
- May 8, 2022
- Last update posted
- May 7, 2024
2020 – 2022
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Merz Investigational Site | Encino | California | 91436 | — |
| Merz Investigational Site | Newport Beach | California | 92663 | — |
| Merz Investigational Site | San Diego | California | 92121 | — |
| Merz Investigational Site | Greenwood Village | Colorado | 80111 | — |
| Merz Investigational Site | Washington D.C. | District of Columbia | 20037 | — |
| Merz Investigational Site | Aventura | Florida | 33180 | — |
| Merz Investigational Site | Boca Raton | Florida | 33431 | — |
| Merz Investigational Site | Metairie | Louisiana | 70006 | — |
| Merz Investigational Site | New York | New York | 10028 | — |
| Merz Investigational Site | New York | New York | 10065 | — |
| Merz Investigational Site | New York | New York | 10075 | — |
| Merz Investigational Site | Nashville | Tennessee | 37215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04594213, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04594213 live on ClinicalTrials.gov.